Niagara Falls, NY – June 13, 2024 (GLOBE NEWSWIRE) – Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce it has secured exclusive rights for the North American market to sell/distribute the NeuSight PET-CT 64 slice scanner through a business cooperation agreement with Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.
The NeuSight PET-CT 64 slice scanner is an award-winning top performing scanner with installations throughout the world. NeuSight PET-CT 64 has FDA clearance to be marketed and sold in the United States which Positron will introduce and sell to the nuclear cardiac imaging market in July 2024.
The NeuSight PET-CT 64 slice is an innovative, economical, PET-CT system which is ideal for clinical exploration, data acquisition and identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology. The NeuSight system serves multiple molecular imaging functions for heart, tumor, and brain imaging studies.
Adel Abdullah, President of Positron stated: “We are excited to bring this PET-CT technology and services to imaging practices and hospitals serving both cardiology and oncology. This is a major step for our company’s entrance into the PET-CT arena which comes at the right time to meet a heightened demand that is stronger than ever. The NeuSight PET-CT has been extremely successful for Neusoft Medical Systems with approximately 500 systems sold internationally, and we are confident for the NeuSight system to have similar success in the US, the largest imaging devices market, as well as Canada and Mexico. NeuSight PET-CT is an ideal versatile scanner suitable for SPECT providers adopting the PET modality as well as oncology practices seeking new systems for enhanced diagnostic and disease management capabilities.” Mr. Abdullah further added, “Positron’s PET-CT and services are the best value of technology and practice sustainability in the industry, and we believe our new system offers the perfect balance of quality, speed, size, and low cost to own and operate for any nuclear medicine provider seeking the best in PET imaging.”
Comentarios